Further research is needed to understand how these medications may influence mental health outcomes across different patient populations
therefore, for this reason it was not used as a target for diabetic therapy, unlike GLP-1
Clinical trials demonstrate that patients lose an average of 15-22% of body weight over 68 weeks, but the timeline for initial results varies based on dose escalation, metabolism, and individual genetic factors
Regulatory Approvals and Guidelines: As GLP-1 receptor agonists receive more regulatory approvals and are recommended in treatment guidelines for diabetes management, their adoption in clinical practice continues to grow, further solidifying their position in the market
Chapman, N
While compounded medications may involve additional considerations compared with FDA-approved products, they may offer alternative formulation or dosing options when deemed appropriate by a prescribing provider